ClinicalTrials.gg
CompletedNCT01271933Updated Jan 22, 2021Results posted

Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients

A Phase 3 interventional study of pregabalin and placebo in Fibromyalgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 52 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-22.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
441
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing pregabalin in Fibromyalgia — 6 open to participants now, 6 under way, none of them phase 3. Pregabalin · Fibromyalgia.

Enrollment
8th of 30
441 · median 199
Started
2011
with 3 others
Phase 3
13 of 30
none open now
Registered
16th of 30
by date
Lead sponsor
15 of 30
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 30 studies testing pregabalin in Fibromyalgia, this one is the 8th largest by enrollment, is one of 4 that started in 2011, is one of 13 in phase 3, and was the 16th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

6 of the 30 studies testing pregabalin in Fibromyalgia are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing pregabalin in Fibromyalgia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of a controlled release formulation of pregabalin administered once daily as compared to placebo in the treatment of fibromyalgia. All patients will receive pregabalin; half of the patients will receive placebo at some point in the study.

03

Conditions studied

  • Fibromyalgia

Keywords

  • fibromyalgia
  • pain
  • pregabalin
  • Lyrica
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have fibromyalgia.

Exclusion criteria

Exclusion Criteria:

  • Patients with other painful conditions cannot participate.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
441 participants (actual)

Study arms

  • Experimental
    Pregabalin

    Drug: pregabalin

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • controlled release tablet; 165-495 mg/day; given once daily

  • Drugplacebo

    matching placebo tablet; given once daily

06

What researchers measure

Primary outcomes

  1. Double-Blind Phase: Time to Loss of Therapeutic Response (LTR)

    The time to loss of therapeutic response (LTR) is the time to loss of pain response (\<30% pain response relative to the single-blind (SB) baseline mean pain) or withdrawal due to lack of efficacy or adverse events (in the double blind phase).

    Time frame: Randomization to Week 19

  2. Double-Blind Phase: Number of Participants With Loss of Therapeutic Response (LTR) Event

    Participants who did not maintain at least 30% pain response during the DB phase relative to baseline or were discontinued during DB due to lack of efficacy or an adverse event were considered to have a loss of therapeutic response.

    Time frame: Randomization to Week 19

Secondary outcomes

  1. Single-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 1, 2, 3, 4, 5, 6

    Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6

  2. Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

    Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).

    Time frame: Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

  3. Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Double Blind Endpoint Visit

    Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).

    Time frame: Baseline, Double blind endpoint visit (Week 19)

  4. Single-Blind Phase: Change From Baseline in Average Daily Tiredness Score at Weeks 1, 2, 3, 4, 5, 6

    The tiredness assessment in the daily interactive voice response system (IVRS) diary consists of an 11-point NRS ranging from zero (not tired) to 10 (extremely tired). Participants rate their tiredness due to fibromyalgia during the past 24 hours by choosing the appropriate number between 0 (not tired) and 10 (extremely tired).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6

  5. Double-Blind Phase: Change From Baseline in Average Daily Tiredness Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

    The tiredness assessment in the daily IVRS diary consists of an 11-point NRS ranging from zero (not tired) to 10 (extremely tired). Participants rate their tiredness due to fibromyalgia during the past 24 hours by choosing the appropriate number between 0 (not tired) and 10 (extremely tired).

    Time frame: Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

  6. Double-Blind Phase: Change From Baseline in Average Daily Tiredness Score at Double Blind Endpoint Visit

    The tiredness assessment in the daily IVRS diary consists of an 11-point NRS ranging from zero (not tired) to 10 (extremely tired). Participants rate their tiredness due to fibromyalgia during the past 24 hours by choosing the appropriate number between 0 (not tired) and 10 (extremely tired).

    Time frame: Baseline, Double blind endpoint visit (Week 19)

  7. Single-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep and Subjective Latency to Sleep Onset at Weeks 1, 2, 3, 4, 5, 6

    The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6

  8. Single-Blind Phase: Change From Baseline in Daily SSQ - Subjective Number of Awakenings After Sleep Onset at Weeks 1, 2, 3, 4, 5, 6

    The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6

  9. Single-Blind Phase: Change From Baseline in Daily SSQ - Subjective Total Sleep Time at Weeks 1, 2, 3, 4, 5, 6

    The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6

  10. Single-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Sleep Quality at Weeks 1, 2, 3, 4, 5, 6

    The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Participants rated quality of sleep during the past night by selecting a number between 0 (very poor) and 10 (excellent). Mean sleep quality was calculated as the mean of the last seven days, the potential range of responses at each week was therefore 0 (very poor) -10 (excellent), where higher scores indicated better quality of sleep.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6

  11. Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep Onset and Subjective Latency to Sleep Onset at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

    The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

    Time frame: Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

  12. Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Number of Awakenings After Sleep Onset at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

    The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

    Time frame: Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

  13. Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Total Sleep Time at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

    The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Subjective total sleep time was the subjective estimate of the total amount of time the participant was asleep after lights out until final awakening.

    Time frame: Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

  14. Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Sleep Quality at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

    The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Participants rated quality of sleep during the past night by selecting a number between 0 (very poor) and 10 (excellent). Mean sleep quality was calculated as the mean of the last seven days, the potential range of responses at each week was therefore 0 (very poor) -10 (excellent), where higher scores indicated better quality of sleep.

    Time frame: Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

  15. Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep Onset and Subjective Latency to Sleep Onset at Double Blind Endpoint Visit

    The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

    Time frame: Baseline, Double blind endpoint visit (Week 19)

  16. Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Number of Awakenings After Sleep Onset at Double Blind Endpoint Visit

    The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

    Time frame: Baseline, Double blind endpoint visit (Week 19)

  17. Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Total Sleep Time at Double Blind Endpoint Visit

    The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

    Time frame: Baseline, Double blind endpoint visit (Week 19)

  18. Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Sleep Quality at Double Blind Endpoint Visit

    The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Participants rated quality of sleep during the past night by selecting a number between 0 (very poor) and 10 (excellent).

    Time frame: Baseline, Double blind endpoint visit (Week 19)

  19. Single-Blind Phase: Change From Baseline in Weekly Pain Score at Week 6 (1 Week Recall Period)

    Weekly pain scores were calculated from the daily pain diary. Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).

    Time frame: Baseline, Week 6

  20. Double-Blind Phase: Change From Baseline in Weekly Pain Score at Week 19 (1 Week Recall Period)

    Weekly pain scores were calculated from the daily pain diary. Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).

    Time frame: Baseline, Week 19

  21. Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 6 - Sleep Disturbance, Snoring, Awakening Short of Breath or With a Headache, Sleep Adequacy, Somnolence, Sleep Problems Index I and Sleep Problems Index II

    The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.

    Time frame: Baseline, Week 6

  22. Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 6- Quantity of Sleep

    The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.

    Time frame: Baseline, Week 6

  23. Double-Blind Phase: Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 19-Sleep Disturbance, Snoring, Awakening Short of Breath or With a Headache, Sleep Adequacy, Somnolence, Sleep Problems Index I and Sleep Problems Index II

    The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.

    Time frame: Baseline, Week 19

  24. Double-Blind Phase: Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 19- Quantity of Sleep

    The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.

    Time frame: Baseline, Week 19

  25. Single-Blind Phase: Number of Participants Who Reported Global Impression of Change (PGIC) at Week 6

    PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse).

    Time frame: Week 6

  26. Double-Blind Phase: Number of Participants Who Reported Global Impression of Change (PGIC) at Week 19

    PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse).

    Time frame: Week 19

  27. Single-Blind Phase: Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 6

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100. Higher scores indicated a better health-related quality of life.

    Time frame: Baseline, Week 6

  28. Double-Blind Phase: Change From Baseline in SF-36 Score at Week 19

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100. Higher scores indicated a better health-related quality of life.

    Time frame: Baseline, Week 19

  29. Single-Blind Phase: Change From Baseline in Hospital Anxiety and Depression Scale (HADS) at Week 6

    HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

    Time frame: Baseline, Week 6

  30. Double-Blind Phase: Change From Baseline in HADS Score at Week 19

    HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

    Time frame: Baseline, Week 19

  31. Single-Blind Phase: Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Week 6

    The FIQ is a 20-item self-administered questionnaire. FIQ contains 10 subscales, which are combined to yield a total score. There are 11 questions that are related specifically to physical functioning (item 1). The remaining questions assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. The FIQ is scored from 0 to 100, with higher scores indicating more impairment.

    Time frame: Baseline, Week 6

  32. Double-Blind Phase: Change From Baseline in FIQ Score at Week 19

    The FIQ is a 20-item self-administered questionnaire. FIQ contains 10 subscales, which are combined to yield a total score. There are 11 questions that are related specifically to physical functioning (item 1). The remaining questions assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. The FIQ is scored from 0 to 100, with higher scores indicating more impairment.

    Time frame: Baseline, Week 19

  33. Single-Blind Phase: Change From Baseline in Multidimensional Fatigue Inventory (MFI) at Week 6

    The MFI is a 20-item, self-administered questionnaire designed to measure the following dimensions of fatigue: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Items are summed to form subscale scores; there is no overall score. The score range is from 4 to 20, where higher scores indicate greater dysfunction.

    Time frame: Baseline, Week 6

  34. Double-Blind Phase: Change From Baseline in MFI Score at Week 19

    The MFI is a 20-item, self-administered questionnaire designed to measure the following dimensions of fatigue: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Items are summed to form subscale scores; there is no overall score. The score range is from 4 to 20, where higher scores indicate greater dysfunction.

    Time frame: Baseline, Week 19

  35. Single-Blind Phase: Number of Participants With Benefit, Satisfaction, Willingness to Continue Measure (BSW) at Week 6

    The questionnaire consists of 3 single-item measures designed to captures the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy.

    Time frame: Week 6

  36. Double-Blind Phase: Number of Participants With Benefit, Satisfaction, and Willingness (BSW) to Continue Data at Visit 9 (3 Component Questions) at Week 19

    The questionnaire consists of 3 single-item measures designed to captures the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy.

    Time frame: Week 19

  37. Single-Blind Phase: Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire at Week 6

    WPAI: 6 question participant rated questionnaire to determine the degree to which disease state affected work productivity while at work and affected activities outside of work. Subscale scores include percent work time missed due to the health problem; percent impairment while working due to problem; percent overall work impairment due to problem; and percent activity impairment due to problem. Scores scaled as 0 (not affected/no impairment) to 10 (completely affected/impaired). Higher scores indicated greater impairment and less productivity.

    Time frame: Baseline, Week 6

  38. Double-Blind Phase: Change From Baseline WPAI Questionnaire at Week 19

    WPAI: 6 question participant rated questionnaire to determine the degree to which disease state affected work productivity while at work and affected activities outside of work. Subscale scores include percent work time missed due to the health problem; percent impairment while working due to problem; percent overall work impairment due to problem; and percent activity impairment due to problem. Scores scaled as 0 (not affected/no impairment) to 10 (completely affected/impaired). Higher scores indicated greater impairment and less productivity.

    Time frame: Baseline, Week 19

  39. Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Daytime Activity at Double Blind End Point Visit (Week 19)

    Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total daytime activity = total activity "counts" during the day.

    Time frame: Baseline, Double blind end point visit (Week 19)

Other outcomes

  1. Single-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Sleep Time at Weeks 3, 4, 5, 6 and 7

    Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total sleep time = number of minutes asleep between time of sleep onset to morning awakening.

    Time frame: Baseline, Weeks 3, 4, 5, 6 and 7

  2. Single-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Minutes of Interrupted Sleep at Weeks 3, 4, 5, 6 and 7

    Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Minutes of interrupted sleep = minutes awake after sleep onset (analogous to wake-time after sleep onset from polysomnography measurements).

    Time frame: Baseline, Weeks 3, 4, 5, 6 and 7

  3. Single-Blind Phase: Change From Baseline at in Actigraphy Functional/Sleep Assessment - Sleep Fragmentation Index Weeks 3, 4, 5, 6 and 7

    Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Sleep fragmentation index = a measure of sleep relatedness. Sleep fragmentation index calculated from analysis of the periods that participant was not moving (immobile bouts). It is number of immobile bouts that were exactly 1 minute long divided by total number of immobile bouts. Value ranges from 0-100 percent, with low number representing more restful sleep.

    Time frame: Baseline, Weeks 3, 4, 5, 6 and 7

  4. Single-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Daytime Activity at Weeks 3, 4, 5, 6 and 7

    Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total daytime activity = total activity "counts" during the day.

    Time frame: Baseline, Weeks 3, 4, 5, 6 and 7

  5. Single-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Percent Sedentary at Weeks 3, 4, 5, 6 and 7

    Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Percent sedentary = percent of daytime spent in sedentary activities as determined by the activity counts measured each minute.

    Time frame: Baseline, Weeks 3, 4, 5, 6 and 7

  6. Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Sleep Time at Weeks 11, 12, 13, 14 and 15

    Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total sleep time = number of minutes asleep between time of sleep onset to morning awakening.

    Time frame: Baseline, Weeks 11, 12, 13, 14 and 15

  7. Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Minutes of Interrupted Sleep at Weeks 11, 12, 13, 14 and 15

    Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Minutes of interrupted sleep = minutes awake after sleep onset (analogous to wake-time after sleep onset from polysomnography measurements).

    Time frame: Baseline, Weeks 11, 12, 13, 14 and 15

  8. Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Sleep Fragmentation Index at Weeks 11, 12, 13, 14 and 15

    Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Sleep fragmentation index = a measure of sleep relatedness. Sleep fragmentation index calculated from analysis of the periods that participant was not moving (immobile bouts). It is number of immobile bouts that were exactly 1 minute long divided by total number of immobile bouts. Value ranges from 0-100 percent, with low number representing more restful sleep.

    Time frame: Baseline, Weeks 11, 12, 13, 14 and 15

  9. Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Daytime Activity at Weeks 11, 12, 13, 14 and 15

    Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total daytime activity = total activity "counts" during the day.

    Time frame: Baseline, Weeks 11, 12, 13, 14 and 15

  10. Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Percent Sedentary at Weeks 11, 12, 13, 14 and 15

    Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Percent sedentary = percent of daytime spent in sedentary activities as determined by the activity counts measured each minute.

    Time frame: Baseline, Weeks 11, 12, 13, 14 and 15

  11. Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment- Total Sleep Time at Double Blind End Point Visit (Week 19)

    Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total sleep time = number of minutes asleep between time of sleep onset to morning awakening.

    Time frame: Baseline, Double blind end point visit (Week 19)

  12. Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Minutes of Interrupted Sleep at Double Blind End Point Visit (Week 19)

    Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Minutes of interrupted sleep = minutes awake after sleep onset (analogous to wake-time after sleep onset from polysomnography measurements).

    Time frame: Baseline, Double blind end point visit (Week 19)

  13. Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Sleep Fragmentation Index at Double Blind End Point Visit (Week 19)

    Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Sleep fragmentation index = a measure of sleep relatedness. Sleep fragmentation index calculated from analysis of the periods that participant was not moving (immobile bouts). It is number of immobile bouts that were exactly 1 minute long divided by total number of immobile bouts. Value ranges from 0-100 percent, with low number representing more restful sleep.

    Time frame: Baseline, Double blind end point visit (Week 19)

  14. Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Percent Sedentary at Double Blind End Point Visit (Week 19)

    Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Percent sedentary = percent of daytime spent in sedentary activities as determined by the activity counts measured each minute.

    Time frame: Baseline, Double blind end point visit (Week 19)

  15. Number of Participants With Suicidal Ideation Throughout the Study Assessed by Columbia Classification Algorithm of Suicide Assessment (C-CASA)

    C-CASA was used to categorize and summarize results from the Sheehan Suicidality Tracking Scale (S-STS) and the Columbia Suicidality Severity Rating Scale (C-SSRS). S-STS was an 8-item prospective rating scale that tracked treatment-emergent suicidal ideation and behaviors. Items 1a, 2 to 6, 7a, 8 were scored on a 5-point Likert scale (ranges 0 \[not at all\] to 4 \[extremely\]). Items 1, 1b, and 7 required yes or no responses. S-STS total score range 0-30. Lower score=reduced suicidal tendency. C-SSRS was a participant rated questionnaire to assess suicidal ideation, suicidal behavior, actual attempts (yes or no responses), and intensity of ideation (rated 1=low severity to 5=high severity). Responses on S-STS or C-SSRS were mapped to C-CASA categories as: Completed suicide; suicide attempt; preparatory acts; suicide ideation; self-injurious behavior, intent unknown; not enough information; self-injurious behavior, no suicide intent; other, no deliberate self harm.

    Time frame: Week 1 to Week 7 and Week 11 to Week 20

07

Results

Posted Sep 14, 2018

Participant flow

The study was performed in 4 countries at 50 centers.

Single-Blind Phase
Participant flow — Single-Blind Phase
MilestonePregabalin (Single Blind Phase)Pregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Started44100
Completed32000
Not completed12100
Withdrew: Lack of efficacy3700
Withdrew: Lost to follow-up1000
Withdrew: Withdrawal by subject1500
Withdrew: Protocol violation300
Withdrew: Adverse event5200
Withdrew: (failed to meet dosing requirement)100
Withdrew: (protocol non-compliance)200
Withdrew: (participant request-personal reason)100
Double-Blind Phase
Participant flow — Double-Blind Phase
MilestonePregabalin (Single Blind Phase)Pregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Started06359
Treated06358
Completed04647
Not completed01712
Withdrew: Randomized but not treated001
Withdrew: Lack of efficacy069
Withdrew: Lost to follow-up011
Withdrew: Withdrawal by subject061
Withdrew: Adverse event030
Withdrew: Participant request-personal reason010

Outcome measures

PrimaryDouble-Blind Phase: Time to Loss of Therapeutic Response (LTR)

The time to loss of therapeutic response (LTR) is the time to loss of pain response (\<30% pain response relative to the single-blind (SB) baseline mean pain) or withdrawal due to lack of efficacy or adverse events (in the double blind phase).

Time frame:
Randomization to Week 19
Reported as:
Median · Days
Double-Blind Phase: Time to Loss of Therapeutic Response (LTR)
DaysPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Double-Blind Phase: Time to Loss of Therapeutic Response (LTR)58 (45 to NA)23 (14 to 41)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · Log Rank · p = 0.0186 (The p-value was calculated using log-rank test for comparing pregabalin CR with placebo)
PrimaryDouble-Blind Phase: Number of Participants With Loss of Therapeutic Response (LTR) Event

Participants who did not maintain at least 30% pain response during the DB phase relative to baseline or were discontinued during DB due to lack of efficacy or an adverse event were considered to have a loss of therapeutic response.

Time frame:
Randomization to Week 19
Reported as:
Count of participants · Participants
Double-Blind Phase: Number of Participants With Loss of Therapeutic Response (LTR) Event
ParticipantsPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Double-Blind Phase: Number of Participants With Loss of Therapeutic Response (LTR) Event3441
SecondarySingle-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 1, 2, 3, 4, 5, 6

Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 6
Reported as:
Mean · Units on a scale
Single-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 1, 2, 3, 4, 5, 6
Units on a scalePregabalin (Single Blind Phase)
Week 1-0.9 ± 1.17
Week 2-1.5 ± 1.51
Week 3-2.0 ± 1.85
Week 4-2.3 ± 2.01
Week 5-2.5 ± 2.00
Week 6-2.6 ± 2.13
SecondaryDouble-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).

Time frame:
Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Reported as:
Mean · Units on a scale
Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Units on a scalePregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Week 7-3.9 ± 1.49-3.0 ± 1.59
Week 8-3.7 ± 1.72-2.7 ± 1.99
Week 9-3.6 ± 2.01-2.8 ± 1.91
Week 10-3.7 ± 1.96-2.4 ± 2.01
Week 11-3.7 ± 2.21-2.6 ± 1.94
Week 12-3.7 ± 1.98-2.6 ± 1.82
Week 13-3.6 ± 2.10-2.6 ± 2.21
Week 14-3.5 ± 2.11-2.5 ± 2.14
Week 15-3.6 ± 2.30-2.6 ± 2.24
Week 16-3.4 ± 2.22-2.6 ± 1.94
Week 17-3.6 ± 2.02-2.5 ± 1.82
Week 18-3.4 ± 2.53-2.5 ± 1.93
Week 19-3.4 ± 2.59-2.4 ± 2.11
Week 20-3.0 ± 2.82-4.9 ± 2.74
SecondaryDouble-Blind Phase: Change From Baseline in Mean Daily Pain Score at Double Blind Endpoint Visit

Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).

Time frame:
Baseline, Double blind endpoint visit (Week 19)
Reported as:
Least squares mean · Units on a scale
Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Double Blind Endpoint Visit
Units on a scalePregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Double Blind Endpoint Visit-2.9 (-3.5 to -2.3)-2.5 (-3.1 to -1.9)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.3310 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model) · Mean difference (final values): -0.4 · 95% CI -1.2 to 0.4
SecondarySingle-Blind Phase: Change From Baseline in Average Daily Tiredness Score at Weeks 1, 2, 3, 4, 5, 6

The tiredness assessment in the daily interactive voice response system (IVRS) diary consists of an 11-point NRS ranging from zero (not tired) to 10 (extremely tired). Participants rate their tiredness due to fibromyalgia during the past 24 hours by choosing the appropriate number between 0 (not tired) and 10 (extremely tired).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 6
Reported as:
Mean · Units on a scale
Single-Blind Phase: Change From Baseline in Average Daily Tiredness Score at Weeks 1, 2, 3, 4, 5, 6
Units on a scalePregabalin (Single Blind Phase)
Week 1-0.7 ± 1.16
Week 2-1.2 ± 1.53
Week 3-1.6 ± 1.91
Week 4-2.0 ± 2.08
Week 5-2.2 ± 2.10
Week 6-2.3 ± 2.17
SecondaryDouble-Blind Phase: Change From Baseline in Average Daily Tiredness Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

The tiredness assessment in the daily IVRS diary consists of an 11-point NRS ranging from zero (not tired) to 10 (extremely tired). Participants rate their tiredness due to fibromyalgia during the past 24 hours by choosing the appropriate number between 0 (not tired) and 10 (extremely tired).

Time frame:
Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Reported as:
Mean · Units on a scale
Double-Blind Phase: Change From Baseline in Average Daily Tiredness Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Units on a scalePregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Week 7-3.4 ± 1.74-3.0 ± 1.79
Week 8-3.3 ± 1.81-2.8 ± 1.95
Week 9-3.2 ± 1.93-2.9 ± 1.98
Week 10-3.2 ± 2.03-2.6 ± 1.93
Week 11-3.1 ± 2.16-2.5 ± 1.91
Week 12-3.4 ± 1.77-2.5 ± 1.69
Week 13-3.2 ± 1.82-2.6 ± 1.87
Week 14-3.2 ± 2.06-2.5 ± 1.95
Week 15-3.4 ± 2.15-2.6 ± 1.96
Week 16-3.1 ± 2.15-2.7 ± 1.84
Week 17-3.4 ± 1.88-2.5 ± 1.96
Week 18-3.2 ± 2.24-2.4 ± 1.82
Week 19-3.1 ± 2.23-2.4 ± 1.96
Week 20-2.7 ± 2.42-4.9 ± 1.48
SecondaryDouble-Blind Phase: Change From Baseline in Average Daily Tiredness Score at Double Blind Endpoint Visit

The tiredness assessment in the daily IVRS diary consists of an 11-point NRS ranging from zero (not tired) to 10 (extremely tired). Participants rate their tiredness due to fibromyalgia during the past 24 hours by choosing the appropriate number between 0 (not tired) and 10 (extremely tired).

Time frame:
Baseline, Double blind endpoint visit (Week 19)
Reported as:
Least squares mean · Units on a scale
Double-Blind Phase: Change From Baseline in Average Daily Tiredness Score at Double Blind Endpoint Visit
Units on a scalePregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Double-Blind Phase: Change From Baseline in Average Daily Tiredness Score at Double Blind Endpoint Visit-2.6 (-3.2 to -2.0)-2.5 (-3.1 to -1.9)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.9247 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.0 · 95% CI -0.8 to 0.8
SecondarySingle-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep and Subjective Latency to Sleep Onset at Weeks 1, 2, 3, 4, 5, 6

The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 6
Reported as:
Mean · Minutes
Single-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep and Subjective Latency to Sleep Onset at Weeks 1, 2, 3, 4, 5, 6
MinutesPregabalin (Single Blind Phase)
Subjective Wake after Sleep Onset (Week 1)-19.1 ± 45.90
Subjective Wake after Sleep Onset (Week 2)-22.4 ± 50.22
Subjective Wake after Sleep Onset (Week 3)-25.0 ± 64.57
Subjective Wake after Sleep Onset (Week 4)-27.5 ± 62.58
Subjective Wake after Sleep Onset (Week 5)-31.4 ± 57.37
Subjective Wake after Sleep Onset (Week 6)-32.8 ± 59.51
Subjective Latency to Sleep Onset (Week 1)-10.3 ± 42.35
Subjective Latency to Sleep Onset (Week 2)-13.0 ± 43.25
Subjective Latency to Sleep Onset (Week 3)-15.5 ± 49.01
Subjective Latency to Sleep Onset (Week 4)-19.6 ± 49.84
Subjective Latency to Sleep Onset (Week 5)-20.0 ± 52.32
Subjective Latency to Sleep Onset (Week 6)-16.9 ± 47.34
SecondarySingle-Blind Phase: Change From Baseline in Daily SSQ - Subjective Number of Awakenings After Sleep Onset at Weeks 1, 2, 3, 4, 5, 6

The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 6
Reported as:
Mean · Number of times the participant awakened
Single-Blind Phase: Change From Baseline in Daily SSQ - Subjective Number of Awakenings After Sleep Onset at Weeks 1, 2, 3, 4, 5, 6
Number of times the participant awakenedPregabalin (Single Blind Phase)
Subjective No.of Awakenings after Sleep (Week 1)-0.8 ± 1.28
Subjective No.of Awakenings after Sleep (Week 2)-1.0 ± 1.50
Subjective No.of Awakenings after Sleep (Week 3)-1.1 ± 1.54
Subjective No.of Awakenings after Sleep (Week 4)-1.1 ± 1.44
Subjective No.of Awakenings after Sleep (Week 5)-1.2 ± 1.70
Subjective No.of Awakenings after Sleep (Week 6)-1.2 ± 1.52
SecondarySingle-Blind Phase: Change From Baseline in Daily SSQ - Subjective Total Sleep Time at Weeks 1, 2, 3, 4, 5, 6

The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 6
Reported as:
Mean · Hours
Single-Blind Phase: Change From Baseline in Daily SSQ - Subjective Total Sleep Time at Weeks 1, 2, 3, 4, 5, 6
HoursPregabalin (Single Blind Phase)
Subjective Total Sleep Time (Week 1)0.6 ± 0.93
Subjective Total Sleep Time (Week 2)0.6 ± 0.96
Subjective Total Sleep Time (Week 3)0.6 ± 1.00
Subjective Total Sleep Time (Week 4)0.7 ± 0.94
Subjective Total Sleep Time (Week 5)0.7 ± 1.00
Subjective Total Sleep Time (Week 6)0.7 ± 1.08
SecondarySingle-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Sleep Quality at Weeks 1, 2, 3, 4, 5, 6

The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Participants rated quality of sleep during the past night by selecting a number between 0 (very poor) and 10 (excellent). Mean sleep quality was calculated as the mean of the last seven days, the potential range of responses at each week was therefore 0 (very poor) -10 (excellent), where higher scores indicated better quality of sleep.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 6
Reported as:
Mean · Units on a scale
Single-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Sleep Quality at Weeks 1, 2, 3, 4, 5, 6
Units on a scalePregabalin (Single Blind Phase)
Sleep quality (Week 1)1.0 ± 1.35
Sleep quality (Week 2)1.2 ± 1.43
Sleep quality (Week 3)1.5 ± 1.75
Sleep quality (Week 4)1.6 ± 1.79
Sleep quality (Week 5)1.7 ± 1.82
Sleep quality (Week 6)1.7 ± 1.89
SecondaryDouble-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep Onset and Subjective Latency to Sleep Onset at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

Time frame:
Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Reported as:
Mean · Minutes
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep Onset and Subjective Latency to Sleep Onset at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
MinutesPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Subjective Wake after Sleep Onset (Week 7)-27.8 ± 37.29-32.0 ± 50.47
Subjective Wake after Sleep Onset (Week 8)-27.4 ± 39.39-28.0 ± 56.99
Subjective Wake after Sleep Onset (Week 9)-27.0 ± 40.12-33.2 ± 56.45
Subjective Wake after Sleep Onset (Week 10)-26.9 ± 38.92-26.2 ± 68.24
Subjective Wake after Sleep Onset (Week 11)-29.0 ± 44.80-37.4 ± 56.79
Subjective Wake after Sleep Onset (Week 12)-26.0 ± 46.00-31.0 ± 43.96
Subjective Wake after Sleep Onset (Week 13)-22.8 ± 37.78-31.4 ± 50.08
Subjective Wake after Sleep Onset (Week 14)-27.0 ± 39.87-43.3 ± 54.45
Subjective Wake after Sleep Onset (Week 15)-31.7 ± 38.37-35.1 ± 56.47
Subjective Wake after Sleep Onset (Week 16)-25.9 ± 41.95-35.0 ± 52.67
Subjective Wake after Sleep Onset (Week 17)-31.5 ± 34.29-36.2 ± 58.67
Subjective Wake after Sleep Onset (Week 18)-32.4 ± 36.37-37.3 ± 56.67
Subjective Wake after Sleep Onset (Week 19)-27.3 ± 52.27-23.1 ± 46.28
Subjective Wake after Sleep Onset (Week 20)-22.5 ± 11.03-7.1 ± 11.15
Subjective Latency to Sleep Onset (Week 7)-15.6 ± 55.67-19.1 ± 41.02
Subjective Latency to Sleep Onset (Week 8)-19.1 ± 29.70-12.3 ± 42.83
Subjective Latency to Sleep Onset (Week 9)-18.4 ± 34.03-16.0 ± 50.97
Subjective Latency to Sleep Onset (Week 10)-19.5 ± 29.40-18.0 ± 43.83
Latency to Sleep Onset (Week 11)-18.5 ± 22.40-18.0 ± 47.82
Subjective Latency to Sleep Onset (Week 12)-16.3 ± 26.04-18.8 ± 40.31
Subjective Latency to Sleep Onset (Week 13)-17.5 ± 20.79-16.8 ± 36.51
Subjective Latency to Sleep Onset (Week 14)-20.8 ± 25.58-21.8 ± 44.03
Subjective Latency to Sleep Onset (Week 15)-19.4 ± 20.25-19.1 ± 42.55
Subjective Latency to Sleep Onset (Week 16)-15.8 ± 31.85-20.9 ± 42.18
Subjective Latency to Sleep Onset (Week 17)-23.1 ± 23.09-20.9 ± 49.30
Subjective Latency to Sleep Onset (Week 18)-16.3 ± 24.52-18.7 ± 46.23
Subjective Latency to Sleep Onset (Week 19)-16.7 ± 29.38-19.5 ± 50.89
Subjective Latency to Sleep Onset (Week 20)23.0 ± 84.31-28.7 ± 8.00
SecondaryDouble-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Number of Awakenings After Sleep Onset at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

Time frame:
Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Reported as:
Mean · Number of times the participant awakened
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Number of Awakenings After Sleep Onset at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Number of times the participant awakenedPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Subjective No.of Awakenings after Sleep (Week 7)-1.1 ± 1.39-1.0 ± 1.30
Subjective No.of Awakenings after Sleep (Week 8)-1.2 ± 1.23-0.8 ± 1.27
Subjective No.of Awakenings after Sleep (Week 9)-1.2 ± 0.94-1.1 ± 1.12
Subjective No.of Awakenings after Sleep (Week 10)-1.2 ± 1.10-0.9 ± 1.16
Subjective No.of Awakenings after Sleep (Week 11)-1.1 ± 1.40-0.9 ± 1.18
Subjective No.of Awakenings after Sleep (Week 12)-1.1 ± 1.50-0.8 ± 1.00
Subjective No.of Awakenings after Sleep (Week 13)-1.0 ± 1.02-1.0 ± 1.13
Subjective No.of Awakenings after Sleep (Week 14)-1.0 ± 1.06-1.1 ± 1.07
Subjective No.of Awakenings after Sleep (Week 15)-0.8 ± 2.20-1.1 ± 1.21
Subjective No.of Awakenings after Sleep (Week 16)-1.0 ± 1.10-1.0 ± 1.18
Subjective No.of Awakenings after Sleep (Week 17)-1.2 ± 0.92-0.9 ± 1.25
Subjective No.of Awakenings after Sleep (Week 18)-1.1 ± 1.14-1.0 ± 1.28
Subjective No.of Awakenings after Sleep (Week 19)-0.7 ± 2.63-0.9 ± 1.32
Subjective No.of Awakenings after Sleep (Week 20)-1.5 ± 1.14-1.5 ± 0.95
SecondaryDouble-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Total Sleep Time at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Subjective total sleep time was the subjective estimate of the total amount of time the participant was asleep after lights out until final awakening.

Time frame:
Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Reported as:
Mean · Hours
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Total Sleep Time at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
HoursPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Subjective Total Sleep Time (Week 7)0.7 ± 1.000.5 ± 1.10
Subjective Total Sleep Time (Week 8)0.9 ± 0.890.6 ± 1.25
Subjective Total Sleep Time (Week 9)0.8 ± 1.000.5 ± 1.10
Subjective Total Sleep Time (Week 10)0.9 ± 1.070.5 ± 1.01
Subjective Total Sleep Time (Week 11)0.9 ± 0.860.6 ± 1.08
Subjective Total Sleep Time (Week 12)0.8 ± 1.010.5 ± 1.13
Subjective Total Sleep Time (Week 13)0.7 ± 0.930.6 ± 0.95
Subjective Total Sleep Time (Week 14)0.9 ± 1.310.7 ± 1.17
Subjective Total Sleep Time (Week 15)0.7 ± 0.900.7 ± 1.22
Subjective Total Sleep Time (Week 16)0.7 ± 0.940.7 ± 1.04
Subjective Total Sleep Time (Week 17)0.7 ± 0.850.7 ± 1.08
Subjective Total Sleep Time (Week 18)0.6 ± 0.850.5 ± 1.23
Subjective Total Sleep Time (Week 19)0.5 ± 1.100.6 ± 1.15
Subjective Total Sleep Time (Week 20)-0.1 ± 1.020.5 ± 0.41
SecondaryDouble-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Sleep Quality at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Participants rated quality of sleep during the past night by selecting a number between 0 (very poor) and 10 (excellent). Mean sleep quality was calculated as the mean of the last seven days, the potential range of responses at each week was therefore 0 (very poor) -10 (excellent), where higher scores indicated better quality of sleep.

Time frame:
Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Reported as:
Mean · Units on a scale
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Sleep Quality at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Units on a scalePregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Sleep Quality (Week 7)1.9 ± 1.691.9 ± 1.62
Sleep Quality (Week 8)2.0 ± 1.611.7 ± 1.71
Sleep Quality (Week 9)2.1 ± 1.471.8 ± 1.66
Sleep Quality (Week 10)2.2 ± 1.701.7 ± 1.74
Sleep Quality (Week 11)2.3 ± 1.781.7 ± 1.63
Sleep Quality (Week 12)2.1 ± 1.661.7 ± 1.65
Sleep Quality (Week 13)1.9 ± 1.721.9 ± 1.63
Sleep Quality (Week 14) N=48,432.2 ± 1.692.1 ± 1.73
Sleep Quality (Week 15)2.2 ± 1.762.0 ± 1.64
Sleep Quality (Week 16)1.9 ± 1.871.9 ± 1.68
Sleep Quality (Week 17)2.2 ± 1.711.9 ± 1.72
Sleep Quality (Week 18)2.1 ± 1.641.8 ± 1.71
Sleep Quality (Week 19)2.0 ± 1.771.5 ± 1.55
Sleep Quality (Week 20)3.1 ± 1.233.3 ± 0.45
SecondaryDouble-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep Onset and Subjective Latency to Sleep Onset at Double Blind Endpoint Visit

The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

Time frame:
Baseline, Double blind endpoint visit (Week 19)
Reported as:
Least squares mean · Minutes
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep Onset and Subjective Latency to Sleep Onset at Double Blind Endpoint Visit
MinutesPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Subjective Wake after Sleep Onset-26.2 (-36.6 to -15.8)-20.6 (-30.7 to -10.5)
Subjective Latency to Sleep Onset-10.6 (-24.2 to 3.0)-11.9 (-25.0 to 1.3)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.4314 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model) · Mean difference (final values): -5.6 · 95% CI -19.7 to 8.5
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.8915 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 1.3 · 95% CI -17.1 to 19.6
SecondaryDouble-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Number of Awakenings After Sleep Onset at Double Blind Endpoint Visit

The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

Time frame:
Baseline, Double blind endpoint visit (Week 19)
Reported as:
Least squares mean · Number of times the participant awakened
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Number of Awakenings After Sleep Onset at Double Blind Endpoint Visit
Number of times the participant awakenedPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Number of Awakenings After Sleep Onset at Double Blind Endpoint Visit-0.5 (-1.1 to 0.1)-0.8 (-1.4 to -0.2)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.4571 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.3 · 95% CI -0.5 to 1.1
SecondaryDouble-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Total Sleep Time at Double Blind Endpoint Visit

The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.

Time frame:
Baseline, Double blind endpoint visit (Week 19)
Reported as:
Least squares mean · Hours
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Total Sleep Time at Double Blind Endpoint Visit
HoursPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Total Sleep Time at Double Blind Endpoint Visit0.6 (0.3 to 0.9)0.4 (0.1 to 0.7)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.3779 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.2 · 95% CI -0.2 to 0.6
SecondaryDouble-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Sleep Quality at Double Blind Endpoint Visit

The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Participants rated quality of sleep during the past night by selecting a number between 0 (very poor) and 10 (excellent).

Time frame:
Baseline, Double blind endpoint visit (Week 19)
Reported as:
Least squares mean · Units on a scale
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Sleep Quality at Double Blind Endpoint Visit
Units on a scalePregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Sleep Quality at Double Blind Endpoint Visit1.9 (1.4 to 2.4)1.4 (1.0 to 1.9)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.2009 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.4 · 95% CI -0.2 to 1.1
SecondarySingle-Blind Phase: Change From Baseline in Weekly Pain Score at Week 6 (1 Week Recall Period)

Weekly pain scores were calculated from the daily pain diary. Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).

Time frame:
Baseline, Week 6
Reported as:
Mean · Units on a scale
Single-Blind Phase: Change From Baseline in Weekly Pain Score at Week 6 (1 Week Recall Period)
Units on a scalePregabalin (Single Blind Phase)
Single-Blind Phase: Change From Baseline in Weekly Pain Score at Week 6 (1 Week Recall Period)-1.6 ± 2.18
SecondaryDouble-Blind Phase: Change From Baseline in Weekly Pain Score at Week 19 (1 Week Recall Period)

Weekly pain scores were calculated from the daily pain diary. Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).

Time frame:
Baseline, Week 19
Reported as:
Least squares mean · Units on a scale
Double-Blind Phase: Change From Baseline in Weekly Pain Score at Week 19 (1 Week Recall Period)
Units on a scalePregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Double-Blind Phase: Change From Baseline in Weekly Pain Score at Week 19 (1 Week Recall Period)-3.1 (-3.8 to -2.4)-2.4 (-3.1 to -1.7)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.1845 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -0.6 · 95% CI -1.6 to 0.3
SecondaryChange From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 6 - Sleep Disturbance, Snoring, Awakening Short of Breath or With a Headache, Sleep Adequacy, Somnolence, Sleep Problems Index I and Sleep Problems Index II

The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.

Time frame:
Baseline, Week 6
Reported as:
Mean · Units on a scale
Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 6 - Sleep Disturbance, Snoring, Awakening Short of Breath or With a Headache, Sleep Adequacy, Somnolence, Sleep Problems Index I and Sleep Problems Index II
Units on a scalePregabalin (Single Blind Phase)
Sleep disturbance-21.8 ± 24.82
Snoring-1.0 ± 24.94
Awakening Short of Breath/with a Headache-11.0 ± 30.59
Sleep adequacy18.9 ± 31.17
Somnolence-3.6 ± 24.87
Sleep Problems Index I-16.1 ± 21.62
Sleep Problems Index II-15.9 ± 20.44
SecondaryChange From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 6- Quantity of Sleep

The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.

Time frame:
Baseline, Week 6
Reported as:
Mean · hours
Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 6- Quantity of Sleep
hoursPregabalin (Single Blind Phase)
Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 6- Quantity of Sleep0.7 ± 1.33
SecondaryDouble-Blind Phase: Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 19-Sleep Disturbance, Snoring, Awakening Short of Breath or With a Headache, Sleep Adequacy, Somnolence, Sleep Problems Index I and Sleep Problems Index II

The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.

Time frame:
Baseline, Week 19
Reported as:
Least squares mean · Units on a scale
Double-Blind Phase: Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 19-Sleep Disturbance, Snoring, Awakening Short of Breath or With a Headache, Sleep Adequacy, Somnolence, Sleep Problems Index I and Sleep Problems Index II
Units on a scalePregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Sleep disturbance-25.4 (-32.0 to -18.8)-15.5 (-21.8 to -9.1)
Snoring-2.4 (-5.2 to 9.9)-2.9 (-10.1 to 4.3)
Awakening Short of Breath/with a Headache-8.1 (-13.5 to -2.7)-4.2 (-9.3 to -0.9)
Sleep adequacy23.9 (16.0 to 31.9)17.1 (9.5 to 24.8)
Somnolence-11.9 (-17.8 to -5.9)-6.6 (-12.4 to -0.9)
Sleep Problems Index I-19.5 (-25.0 to -13.9)-13.7 (-19.0 to -8.3)
Sleep Problems Index II-19.7 (-25.4 to -14.0)-14.0 (-19.5 to -8.6)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.0305 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -9.9 · 95% CI -18.9 to 1.0
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.3133 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 5.2 · 95% CI -5.0 to 15.5
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.2985 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -3.9 · 95% CI -11.2 to 3.5
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.2159 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 6.8 · 95% CI -4.1 to 17.7
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.2041 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -5.2 · 95% CI -13.4 to 2.9
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.1319 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -5.8 · 95% CI -13.4 to 1.8
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.1473 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -5.7 · 95% CI -13.4 to 2.0
SecondaryDouble-Blind Phase: Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 19- Quantity of Sleep

The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.

Time frame:
Baseline, Week 19
Reported as:
Least squares mean · hours
Double-Blind Phase: Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 19- Quantity of Sleep
hoursPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Double-Blind Phase: Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 19- Quantity of Sleep0.7 (0.4 to 1.0)0.5 (0.2 to 0.8)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.3596 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.2 · 95% CI -0.2 to 0.6
SecondarySingle-Blind Phase: Number of Participants Who Reported Global Impression of Change (PGIC) at Week 6

PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse).

Time frame:
Week 6
Reported as:
Number · Participants
Single-Blind Phase: Number of Participants Who Reported Global Impression of Change (PGIC) at Week 6
ParticipantsPregabalin (Single Blind Phase)
Very Much Improved24
Much Improved77
Minimally Improved103
No Change46
Minimally Worse16
Much Worse18
Very Much Worse5
SecondaryDouble-Blind Phase: Number of Participants Who Reported Global Impression of Change (PGIC) at Week 19

PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse).

Time frame:
Week 19
Reported as:
Number · Participants
Double-Blind Phase: Number of Participants Who Reported Global Impression of Change (PGIC) at Week 19
ParticipantsPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Very Much Improved77
Much Improved1511
Minimally Improved1412
No Change911
Minimally Worse76
Much Worse78
Very Much Worse12
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · two-sided test · p = 0.4985 (Nominal p-value for two-sided test.) · Odds ratio (or): 1.25 · 95% CI 0.66 to 2.36
SecondarySingle-Blind Phase: Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 6

SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100. Higher scores indicated a better health-related quality of life.

Time frame:
Baseline, Week 6
Reported as:
Mean · Units on a scale
Single-Blind Phase: Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 6
Units on a scalePregabalin (Single Blind Phase)
SF-36 Physical Functioning14.0 ± 19.89
SF-36 Role-Physical17.8 ± 27.38
SF-36 Pain Index20.7 ± 22.07
SF-36 General Health Perceptions8.5 ± 17.96
SF-36 Vitality18.2 ± 24.35
SF-36 Social Functioning12.9 ± 28.19
SF-36 Role-Emotional8.6 ± 29.40
SF-36 Mental Health Index7.9 ± 18.94
Physical Component Score7.2 ± 8.75
Mental Component Score4.5 ± 11.78
SecondaryDouble-Blind Phase: Change From Baseline in SF-36 Score at Week 19

SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100. Higher scores indicated a better health-related quality of life.

Time frame:
Baseline, Week 19
Reported as:
Least squares mean · Units on a scale
Double-Blind Phase: Change From Baseline in SF-36 Score at Week 19
Units on a scalePregabalin (Double Blind Phase)Placebo (Double Blind Phase)
SF-36 Physical Functioning12.4 (6.4 to 18.4)13.7 (8.0 to 19.5)
SF-36 Role-Physical18.9 (11.7 to 26.0)16.2 (9.4 to 23.1)
SF-36 Pain Index19.2 (12.5 to 26.0)16.0 (9.5 to 22.5)
SF-36 General Health Perceptions3.3 (-1.8 to 8.3)9.3 (4.5 to 14.2)
SF-36 Vitality12.2 (5.3 to 19.1)15.7 (9.1 to 22.3)
SF-36 Social Functioning13.3 (7.0 to 19.6)13.5 (7.4 to 19.5)
SF-36 Role-Emotional3.8 (-4.1 to 11.7)2.2 (-5.4 to 9.8)
SF-36 Mental Health Index6.6 (1.4 to 11.7)5.2 (0.3 to 10.2)
Physical Component Score6.8 (4.2 to 9.4)7.2 (4.7 to 9.7)
Mental Component Score2.6 (-0.6 to 5.8)2.4 (-0.7 to 5.5)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.7400 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -1.4 · 95% CI -9.5 to 6.8
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.5938 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 2.6 · 95% CI -7.1 to 12.3
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.4842 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 3.2 · 95% CI -5.9 to 12.4
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.0827 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model) · Mean difference (final values): -6.1 · 95% CI -12.9 to 0.8
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.4561 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -3.5 · 95% CI -12.09 to 5.8
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.9645 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -0.2 · 95% CI -8.8 to 8.4
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.7636 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 1.6 · 95% CI -9.1 to 12.4
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.7067 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 1.3 · 95% CI -5.7 to 8.4
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.8352 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -0.4 · 95% CI -3.9 to 3.2
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.9347 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.2 · 95% CI -4.2 to 4.6
SecondarySingle-Blind Phase: Change From Baseline in Hospital Anxiety and Depression Scale (HADS) at Week 6

HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

Time frame:
Baseline, Week 6
Reported as:
Mean · Units on a scale
Single-Blind Phase: Change From Baseline in Hospital Anxiety and Depression Scale (HADS) at Week 6
Units on a scalePregabalin (Single Blind Phase)
HADS-A Anxiety scale-1.8 ± 3.47
HADS-D Depression scale-1.5 ± 3.62
SecondaryDouble-Blind Phase: Change From Baseline in HADS Score at Week 19

HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

Time frame:
Baseline, Week 19
Reported as:
Least squares mean · Units on a scale
Double-Blind Phase: Change From Baseline in HADS Score at Week 19
Units on a scalePregabalin (Double Blind Phase)Placebo (Double Blind Phase)
HADS-A Anxiety scale-0.7 (-1.7 to 0.4)-1.6 (-2.6 to -0.6)
HADS-D Depression scale-1.4 (-2.3 to -0.4)-1.1 (-2.0 to -0.2)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.1901 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.9 · 95% CI -0.5 to 2.3
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.6914 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -0.3 · 95% CI -1.6 to 1.0
SecondarySingle-Blind Phase: Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Week 6

The FIQ is a 20-item self-administered questionnaire. FIQ contains 10 subscales, which are combined to yield a total score. There are 11 questions that are related specifically to physical functioning (item 1). The remaining questions assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. The FIQ is scored from 0 to 100, with higher scores indicating more impairment.

Time frame:
Baseline, Week 6
Reported as:
Mean · Units on a scale
Single-Blind Phase: Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Week 6
Units on a scalePregabalin (Single Blind Phase)
Item 1: Physical activities-0.9 ± 2.14
Item 2: Feel good-2.2 ± 3.33
Item 3: Work missed-0.5 ± 2.42
Item 4: Do job-1.5 ± 2.72
Item 5: Pain-1.6 ± 2.25
Item 6: Fatigue-1.4 ± 2.43
Item 7: Rested-1.7 ± 2.65
Item 8: Stiffness-1.8 ± 2.65
Item 9: Anxiety-1.2 ± 2.95
Item 10: Depression-0.6 ± 2.75
Total Score-13.4 ± 16.71
SecondaryDouble-Blind Phase: Change From Baseline in FIQ Score at Week 19

The FIQ is a 20-item self-administered questionnaire. FIQ contains 10 subscales, which are combined to yield a total score. There are 11 questions that are related specifically to physical functioning (item 1). The remaining questions assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. The FIQ is scored from 0 to 100, with higher scores indicating more impairment.

Time frame:
Baseline, Week 19
Reported as:
Least squares mean · Units on a scale
Double-Blind Phase: Change From Baseline in FIQ Score at Week 19
Units on a scalePregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Item 1: Physical activities-1.0 (-1.6 to -0.4)-1.3 (-1.9 to -0.8)
Item 2: feel good-3.0 (-3.9 to -2.1)-3.2 (-4.1 to -2.3)
Item 3: Work missed-1.2 (-1.7 to -0.7)-1.0 (-1.5 to -0.5)
Item 4: Do job-2.1 (-3.0 to -1.3)-2.2 (-3.0 to -1.4)
Item 5: Pain-2.7 (-3.4 to -2.0)-2.2 (-2.8 to -1.5)
Item 6: Fatigue-2.3 (-3.0 to -1.6)-2.4 (-3.0 to -1.7)
Item 7: Rested-2.6 (-3.4 to -1.8)-2.2 (-3.0 to -1.4)
Item 8: Stiffness-2.4 (-3.2 to -1.6)-2.2 (-3.0 to -1.4)
Item 9: Anxiety-1.8 (-2.6 to -1.0)-1.7 (-2.5 to -0.9)
Item 10: Depression-0.7 (-1.4 to -0.0)-0.7 (-1.3 to 0.0)
Total Score-19.6 (-25.3 to -13.9)-19.1 (-24.6 to -13.7)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.3721 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.4 · 95% CI -0.5 to 1.2
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.8084 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.2 · 95% CI -1.1 to 1.4
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.6312 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -0.2 · 95% CI -0.9 to 0.5
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.8824 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.1 · 95% CI -1.0 to 1.2
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.2742 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -0.5 · 95% CI -1.5 to 0.4
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.8520 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.1 · 95% CI -0.8 to 1.0
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.5264 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -0.3 · 95% CI -1.4 to 0.7
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.6601 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -0.2 · 95% CI -1.3 to 0.9
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.8937 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -0.1 · 95% CI -1.2 to 1.0
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.9151 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -0.1 · 95% CI -1.0 to 0.9
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.9045 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -0.5 · 95% CI -8.2 to 7.3
SecondarySingle-Blind Phase: Change From Baseline in Multidimensional Fatigue Inventory (MFI) at Week 6

The MFI is a 20-item, self-administered questionnaire designed to measure the following dimensions of fatigue: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Items are summed to form subscale scores; there is no overall score. The score range is from 4 to 20, where higher scores indicate greater dysfunction.

Time frame:
Baseline, Week 6
Reported as:
Mean · Units on a scale
Single-Blind Phase: Change From Baseline in Multidimensional Fatigue Inventory (MFI) at Week 6
Units on a scalePregabalin (Single Blind Phase)
General fatigue-0.2 ± 2.47
Physical fatigue0.1 ± 2.67
Reduced activity-0.2 ± 2.55
Reduced motivation0.2 ± 2.71
Mental fatigue-0.1 ± 2.17
SecondaryDouble-Blind Phase: Change From Baseline in MFI Score at Week 19

The MFI is a 20-item, self-administered questionnaire designed to measure the following dimensions of fatigue: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Items are summed to form subscale scores; there is no overall score. The score range is from 4 to 20, where higher scores indicate greater dysfunction.

Time frame:
Baseline, Week 19
Reported as:
Least squares mean · Units on a scale
Double-Blind Phase: Change From Baseline in MFI Score at Week 19
Units on a scalePregabalin (Double Blind Phase)Placebo (Double Blind Phase)
General fatigue0.1 (-0.4 to 0.6)-0.1 (-0.6 to 0.3)
Physical fatigue-0.1 (-0.6 to 0.5)0.2 (-0.3 to 0.7)
Reduced activity0.0 (-0.5 to 0.6)-0.3 (-0.7 to 0.2)
Reduced motivation1.0 (0.4 to 1.5)0.3 (-0.2 to 0.8)
Mental fatigue-0.1 (-0.5 to 0.3)0.1 (-0.3 to 0.4)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.4606 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.2 · 95% CI -0.4 to 0.9
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.4703 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -0.3 · 95% CI -1.0 to 0.5
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.4009 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.3 · 95% CI -0.4 to 1.0
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.0695 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.6 · 95% CI -0.1 to 1.3
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.5869 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -0.1 · 95% CI -0.7 to 0.4
SecondarySingle-Blind Phase: Number of Participants With Benefit, Satisfaction, Willingness to Continue Measure (BSW) at Week 6

The questionnaire consists of 3 single-item measures designed to captures the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy.

Time frame:
Week 6
Reported as:
Number · Participants
Single-Blind Phase: Number of Participants With Benefit, Satisfaction, Willingness to Continue Measure (BSW) at Week 6
ParticipantsPregabalin (Single Blind Phase)
Benefit from treatment-No69
Benefit from treatment-Little benefit137
Benefit from treatment-much benefit211
Satisfaction from treatment-very dissatisfied52
Satisfaction from treatment-a little dissatisfied59
Satisfaction from treatment-a little satisfied103
Satisfaction from treatment-very satisfied203
Willing to continue treatment-very unwilling68
Willing to continue treatment-little unwilling33
Willing to continue treatment-little bit willing49
Willing to continue treatment-very willing266
SecondaryDouble-Blind Phase: Number of Participants With Benefit, Satisfaction, and Willingness (BSW) to Continue Data at Visit 9 (3 Component Questions) at Week 19

The questionnaire consists of 3 single-item measures designed to captures the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy.

Time frame:
Week 19
Reported as:
Number · Participants
Double-Blind Phase: Number of Participants With Benefit, Satisfaction, and Willingness (BSW) to Continue Data at Visit 9 (3 Component Questions) at Week 19
ParticipantsPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Benefit from treatment-No311
Benefit from treatment-Little benefit1516
Benefit from treatment-much benefit4130
Satisfaction from treatment-very dissatisfied46
Satisfaction from treatment-a little dissatisfied108
Satisfaction from treatment-a little satisfied1013
Satisfaction from treatment-very satisfied3630
Willing to continue treatment-very unwilling84
Willing to continue treatment-little unwilling68
Willing to continue treatment-little bit willing911
Willing to continue treatment-very willing3734
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · two-sided test · p = 0.0296 (Nominal p-value for two-sided test.) · Odds ratio (or): 2.29 · 95% CI 1.09 to 4.81
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · two-sided test · p = 0.4691 (Nominal p-value for two-sided test) · Odds ratio (or): 1.29 · 95% CI 0.64 to 2.61
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · two-sided test · p = 0.9577 (Nominal p-value for two-sided test) · Odds ratio (or): 0.98 · 95% CI 0.48 to 2.01
SecondarySingle-Blind Phase: Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire at Week 6

WPAI: 6 question participant rated questionnaire to determine the degree to which disease state affected work productivity while at work and affected activities outside of work. Subscale scores include percent work time missed due to the health problem; percent impairment while working due to problem; percent overall work impairment due to problem; and percent activity impairment due to problem. Scores scaled as 0 (not affected/no impairment) to 10 (completely affected/impaired). Higher scores indicated greater impairment and less productivity.

Time frame:
Baseline, Week 6
Reported as:
Mean · Units on a scale
Single-Blind Phase: Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire at Week 6
Units on a scalePregabalin (Single Blind Phase)
Percent Work Time Missed-5.8 ± 48.69
Percent Impairment While Working-10.0 ± 31.29
Percent Activity Impairment-13.5 ± 25.88
Percent Overall Work Impairment-12.3 ± 27.62
SecondaryDouble-Blind Phase: Change From Baseline WPAI Questionnaire at Week 19

WPAI: 6 question participant rated questionnaire to determine the degree to which disease state affected work productivity while at work and affected activities outside of work. Subscale scores include percent work time missed due to the health problem; percent impairment while working due to problem; percent overall work impairment due to problem; and percent activity impairment due to problem. Scores scaled as 0 (not affected/no impairment) to 10 (completely affected/impaired). Higher scores indicated greater impairment and less productivity.

Time frame:
Baseline, Week 19
Reported as:
Least squares mean · Units on a scale
Double-Blind Phase: Change From Baseline WPAI Questionnaire at Week 19
Units on a scalePregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Percent Work Time Missed-7.3 (-21.3 to 6.7)-26.7 (-41.0 to -12.3)
Percent Impairment While Working-14.0 (-19.7 to -8.2)-15.0 (-20.8 to -9.3)
Percent Activity Impairment-16.4 (-19.0 to -13.7)-19.6 (-22.1 to -17.0)
Percent Overall Work Impairment-15.9 (-18.7 to -13.1)-17.5 (-20.2 to -14.8)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.0562 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 19.3 · 95% CI -0.5 to 39.2
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.7892 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 1.1 · 95% CI -7.0 to 9.2
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.0819 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 3.2 · 95% CI -0.4 to 6.8
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.4135 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 1.6 · 95% CI -2.2 to 5.4
Other pre-specifiedSingle-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Sleep Time at Weeks 3, 4, 5, 6 and 7

Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total sleep time = number of minutes asleep between time of sleep onset to morning awakening.

Time frame:
Baseline, Weeks 3, 4, 5, 6 and 7
Reported as:
Mean · Hours
Single-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Sleep Time at Weeks 3, 4, 5, 6 and 7
HoursPregabalin (Single Blind Phase)
Total Sleep Time (Week 3)-0.1 ± 0.94
Total Sleep Time (Week 4)0.4 ± 0.99
Total Sleep Time (Week 5)0.3 ± 1.02
Total Sleep Time (Week 6)0.3 ± 1.15
Total Sleep Time (Week 7)0.6 ± 1.10
Other pre-specifiedSingle-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Minutes of Interrupted Sleep at Weeks 3, 4, 5, 6 and 7

Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Minutes of interrupted sleep = minutes awake after sleep onset (analogous to wake-time after sleep onset from polysomnography measurements).

Time frame:
Baseline, Weeks 3, 4, 5, 6 and 7
Reported as:
Mean · Minutes
Single-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Minutes of Interrupted Sleep at Weeks 3, 4, 5, 6 and 7
MinutesPregabalin (Single Blind Phase)
Minutes of Interrupted Sleep (Week 3)-5.3 ± 12.63
Minutes of Interrupted Sleep (Week 4)-5.9 ± 16.10
Minutes of Interrupted Sleep (Week 5)-7.0 ± 15.66
Minutes of Interrupted Sleep (Week 6)-6.6 ± 16.12
Minutes of Interrupted Sleep (Week 7)0.7 ± 19.43
Other pre-specifiedSingle-Blind Phase: Change From Baseline at in Actigraphy Functional/Sleep Assessment - Sleep Fragmentation Index Weeks 3, 4, 5, 6 and 7

Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Sleep fragmentation index = a measure of sleep relatedness. Sleep fragmentation index calculated from analysis of the periods that participant was not moving (immobile bouts). It is number of immobile bouts that were exactly 1 minute long divided by total number of immobile bouts. Value ranges from 0-100 percent, with low number representing more restful sleep.

Time frame:
Baseline, Weeks 3, 4, 5, 6 and 7
Reported as:
Mean · Percentage of immobile bouts
Single-Blind Phase: Change From Baseline at in Actigraphy Functional/Sleep Assessment - Sleep Fragmentation Index Weeks 3, 4, 5, 6 and 7
Percentage of immobile boutsPregabalin (Single Blind Phase)
Sleep Fragmentation Index (Week 3)-0.8 ± 5.27
Sleep Fragmentation Index (Week 4)-2.5 ± 5.45
Sleep Fragmentation Index (Week 5)-2.8 ± 5.27
Sleep Fragmentation Index (Week 6)-2.6 ± 5.63
Sleep Fragmentation Index (Week 7)0.7 ± 5.85
Other pre-specifiedSingle-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Daytime Activity at Weeks 3, 4, 5, 6 and 7

Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total daytime activity = total activity "counts" during the day.

Time frame:
Baseline, Weeks 3, 4, 5, 6 and 7
Reported as:
Mean · Counts of total daytime activity
Single-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Daytime Activity at Weeks 3, 4, 5, 6 and 7
Counts of total daytime activityPregabalin (Single Blind Phase)
Total daytime activity (Week 3)10264.3 ± 90090.07
Total daytime activity (Week 4)10588.1 ± 59150.38
Total daytime activity (Week 5)8635.8 ± 54823.64
Total daytime activity (Week 6)7134.2 ± 58221.22
Total daytime activity (Week 7)18420.7 ± 61725.84
Other pre-specifiedSingle-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Percent Sedentary at Weeks 3, 4, 5, 6 and 7

Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Percent sedentary = percent of daytime spent in sedentary activities as determined by the activity counts measured each minute.

Time frame:
Baseline, Weeks 3, 4, 5, 6 and 7
Reported as:
Mean · Percent of daytime
Single-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Percent Sedentary at Weeks 3, 4, 5, 6 and 7
Percent of daytimePregabalin (Single Blind Phase)
Percent Sedentary (Week 3)0.7 ± 6.66
Percent Sedentary (Week 4)0.7 ± 5.61
Percent Sedentary (Week 5)0.6 ± 5.62
Percent Sedentary (Week 6)0.3 ± 6.07
Percent Sedentary (Week 7)0.2 ± 5.51
Other pre-specifiedDouble-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Sleep Time at Weeks 11, 12, 13, 14 and 15

Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total sleep time = number of minutes asleep between time of sleep onset to morning awakening.

Time frame:
Baseline, Weeks 11, 12, 13, 14 and 15
Reported as:
Mean · Hours
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Sleep Time at Weeks 11, 12, 13, 14 and 15
HoursPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Total Sleep Time (Week 11)0.5 ± 0.910.0 ± 1.53
Total Sleep Time (Week 12)0.5 ± 1.230.1 ± 1.01
Total Sleep Time (Week 13)0.4 ± 1.150.1 ± 1.15
Total Sleep Time (Week 14)0.4 ± 1.020.1 ± 1.14
Total Sleep Time (Week 15)0.2 ± 0.910.3 ± 1.13
Other pre-specifiedDouble-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Minutes of Interrupted Sleep at Weeks 11, 12, 13, 14 and 15

Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Minutes of interrupted sleep = minutes awake after sleep onset (analogous to wake-time after sleep onset from polysomnography measurements).

Time frame:
Baseline, Weeks 11, 12, 13, 14 and 15
Reported as:
Mean · Minutes
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Minutes of Interrupted Sleep at Weeks 11, 12, 13, 14 and 15
MinutesPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Minutes of Interrupted Sleep (Week 11)-9.0 ± 10.272.5 ± 18.97
Minutes of Interrupted Sleep (Week 12)-3.0 ± 14.77-1.7 ± 14.10
Minutes of Interrupted Sleep (Week 13)-3.0 ± 20.330.4 ± 14.14
Minutes of Interrupted Sleep (Week 14)-3.2 ± 19.12-1.8 ± 13.19
Minutes of Interrupted Sleep (Week 15)-0.4 ± 25.03-0.5 ± 13.73
Other pre-specifiedDouble-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Sleep Fragmentation Index at Weeks 11, 12, 13, 14 and 15

Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Sleep fragmentation index = a measure of sleep relatedness. Sleep fragmentation index calculated from analysis of the periods that participant was not moving (immobile bouts). It is number of immobile bouts that were exactly 1 minute long divided by total number of immobile bouts. Value ranges from 0-100 percent, with low number representing more restful sleep.

Time frame:
Baseline, Weeks 11, 12, 13, 14 and 15
Reported as:
Mean · Percentage of immobile bouts
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Sleep Fragmentation Index at Weeks 11, 12, 13, 14 and 15
Percentage of immobile boutsPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Sleep Fragmentation Index (Week 11)-4.4 ± 5.530.1 ± 5.17
Sleep Fragmentation Index (Week 12)-2.8 ± 5.91-0.4 ± 6.29
Sleep Fragmentation Index (Week 13)-2.2 ± 7.28-0.3 ± 5.23
Sleep Fragmentation Index (Week 14)-2.4 ± 7.32-0.6 ± 4.75
Sleep Fragmentation Index (Week 15)-0.9 ± 7.41-0.9 ± 5.19
Other pre-specifiedDouble-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Daytime Activity at Weeks 11, 12, 13, 14 and 15

Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total daytime activity = total activity "counts" during the day.

Time frame:
Baseline, Weeks 11, 12, 13, 14 and 15
Reported as:
Mean · Counts of total daytime activity
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Daytime Activity at Weeks 11, 12, 13, 14 and 15
Counts of total daytime activityPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Total daytime activity (Week 11)-1894.1 ± 46879.81-2083.9 ± 40939.67
Total daytime activity ((Week 12)-50.7 ± 50114.87-6691.1 ± 47353.03
Total daytime activity ((Week 13)-4362.4 ± 51922.75521.8 ± 46996.71
Total daytime activity ((Week 14)-179.7 ± 55858.35-4523.8 ± 52629.95
Total daytime activity ((Week 15)-4138.3 ± 54924.02-4649.4 ± 58121.16
Other pre-specifiedDouble-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Percent Sedentary at Weeks 11, 12, 13, 14 and 15

Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Percent sedentary = percent of daytime spent in sedentary activities as determined by the activity counts measured each minute.

Time frame:
Baseline, Weeks 11, 12, 13, 14 and 15
Reported as:
Mean · Percent of daytime
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Percent Sedentary at Weeks 11, 12, 13, 14 and 15
Percent of daytimePregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Percent Sedentary (Week 11)-0.7 ± 7.721.1 ± 6.69
Percent Sedentary (Week 12)-0.8 ± 5.66-1.4 ± 6.15
Percent Sedentary (Week 13)-1.3 ± 5.41-0.9 ± 6.15
Percent Sedentary (Week 14)-2.1 ± 6.56-1.1 ± 7.27
Percent Sedentary (Week 15)-1.5 ± 5.21-1.4 ± 6.56
Other pre-specifiedDouble-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment- Total Sleep Time at Double Blind End Point Visit (Week 19)

Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total sleep time = number of minutes asleep between time of sleep onset to morning awakening.

Time frame:
Baseline, Double blind end point visit (Week 19)
Reported as:
Least squares mean · Hours
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment- Total Sleep Time at Double Blind End Point Visit (Week 19)
HoursPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment- Total Sleep Time at Double Blind End Point Visit (Week 19)0.5 (0.1 to 0.9)0.1 (-0.3 to 0.5)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.1224 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.4 · 95% CI -0.1 to 0.9
Other pre-specifiedDouble-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Minutes of Interrupted Sleep at Double Blind End Point Visit (Week 19)

Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Minutes of interrupted sleep = minutes awake after sleep onset (analogous to wake-time after sleep onset from polysomnography measurements).

Time frame:
Baseline, Double blind end point visit (Week 19)
Reported as:
Least squares mean · Minutes
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Minutes of Interrupted Sleep at Double Blind End Point Visit (Week 19)
MinutesPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Minutes of Interrupted Sleep at Double Blind End Point Visit (Week 19)-3.5 (-10.0 to 2.9)-2.3 (-8.8 to 4.1)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.7680 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -1.2 · 95% CI -9.3 to 6.9
Other pre-specifiedDouble-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Sleep Fragmentation Index at Double Blind End Point Visit (Week 19)

Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Sleep fragmentation index = a measure of sleep relatedness. Sleep fragmentation index calculated from analysis of the periods that participant was not moving (immobile bouts). It is number of immobile bouts that were exactly 1 minute long divided by total number of immobile bouts. Value ranges from 0-100 percent, with low number representing more restful sleep.

Time frame:
Baseline, Double blind end point visit (Week 19)
Reported as:
Least squares mean · Percentage of immobile bouts
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Sleep Fragmentation Index at Double Blind End Point Visit (Week 19)
Percentage of immobile boutsPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Sleep Fragmentation Index at Double Blind End Point Visit (Week 19)-2.5 (-4.6 to -0.5)-0.6 (-2.6 to 1.4)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.1360 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): -1.9 · 95% CI -4.5 to 0.6
SecondaryDouble-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Daytime Activity at Double Blind End Point Visit (Week 19)

Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total daytime activity = total activity "counts" during the day.

Time frame:
Baseline, Double blind end point visit (Week 19)
Reported as:
Least squares mean · Counts of total daytime activity
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Daytime Activity at Double Blind End Point Visit (Week 19)
Counts of total daytime activityPregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Daytime Activity at Double Blind End Point Visit (Week 19)-182.7 (-20143.1 to 19777.7)-6672.2 (-26663.5 to 13319.1)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.6077 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 6489.5 · 95% CI -18648.6 to 31627.6
Other pre-specifiedDouble-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Percent Sedentary at Double Blind End Point Visit (Week 19)

Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Percent sedentary = percent of daytime spent in sedentary activities as determined by the activity counts measured each minute.

Time frame:
Baseline, Double blind end point visit (Week 19)
Reported as:
Least squares mean · Percent of daytime
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Percent Sedentary at Double Blind End Point Visit (Week 19)
Percent of daytimePregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Percent Sedentary at Double Blind End Point Visit (Week 19)-1.4 (-3.6 to 0.8)-2.0 (-4.2 to 0.2)
Statistical analysis
  • Pregabalin (Double Blind Phase) vs Placebo (Double Blind Phase) · ANCOVA · p = 0.6647 (Estimates and p-values are from a ANCOVA main effects model with baseline value, center, treatment in the model.) · Mean difference (final values): 0.6 · 95% CI -2.2 to 3.4
Other pre-specifiedNumber of Participants With Suicidal Ideation Throughout the Study Assessed by Columbia Classification Algorithm of Suicide Assessment (C-CASA)

C-CASA was used to categorize and summarize results from the Sheehan Suicidality Tracking Scale (S-STS) and the Columbia Suicidality Severity Rating Scale (C-SSRS). S-STS was an 8-item prospective rating scale that tracked treatment-emergent suicidal ideation and behaviors. Items 1a, 2 to 6, 7a, 8 were scored on a 5-point Likert scale (ranges 0 \[not at all\] to 4 \[extremely\]). Items 1, 1b, and 7 required yes or no responses. S-STS total score range 0-30. Lower score=reduced suicidal tendency. C-SSRS was a participant rated questionnaire to assess suicidal ideation, suicidal behavior, actual attempts (yes or no responses), and intensity of ideation (rated 1=low severity to 5=high severity). Responses on S-STS or C-SSRS were mapped to C-CASA categories as: Completed suicide; suicide attempt; preparatory acts; suicide ideation; self-injurious behavior, intent unknown; not enough information; self-injurious behavior, no suicide intent; other, no deliberate self harm.

Time frame:
Week 1 to Week 7 and Week 11 to Week 20
Reported as:
Number · Participants
Number of Participants With Suicidal Ideation Throughout the Study Assessed by Columbia Classification Algorithm of Suicide Assessment (C-CASA)
ParticipantsPregabalin (Single Blind Phase)Pregabalin (Double Blind Phase)Placebo (Double Blind Phase)
Week 15——
Week 26——
Week 34——
Week 616——
Week 710——
Week 11—30
Week 15—11
Week 19—13
Week 20—11

Adverse events

Collected over From time that the participant provided informed consent through and including 28 calender days after the last administration of the investigational product (up to Week 20). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin (Single Blind Phase)—5/441 (1.1%)353/441 (80%)
Pregabalin (Double Blind Phase)—2/63 (3.2%)34/63 (54%)
Placebo (Double Blind Phase)—0/58 (0%)27/58 (46.6%)
Most frequent serious events
Most frequent serious events
EventPregabalin (Single Blind Phase)Pregabalin (Double Blind Phase)Placebo (Double Blind Phase)
VertigoEar and labyrinth disorders0/4411/630/58
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4411/630/58
GlossitisGastrointestinal disorders1/4410/630/58
Chest painGeneral disorders1/4410/630/58
CellulitisInfections and infestations1/4410/630/58
PneumoniaInfections and infestations1/4410/630/58
HypertensionInvestigations1/4410/630/58
Post-traumatic stress disorderPsychiatric disorders1/4410/630/58
Most frequent other events
Showing 10 of 271
Most frequent other events
EventPregabalin (Single Blind Phase)Pregabalin (Double Blind Phase)Placebo (Double Blind Phase)
DizzinessNervous system disorders161/4412/632/58
SomnolenceNervous system disorders105/4410/630/58
HeadacheNervous system disorders43/4411/632/58
FatigueGeneral disorders42/4411/630/58
Oedema peripheralGeneral disorders27/4416/632/58
NauseaGastrointestinal disorders41/4415/630/58
Weight increasedInvestigations30/4412/631/58
Vision blurredEye disorders29/4411/630/58
Dry mouthGastrointestinal disorders25/4410/632/58
Disturbance in attentionNervous system disorders24/4410/630/58

Baseline characteristics

Single-blind analysis set (SBAS) consisted of all participants who were enrolled into the SB phase of the study and received at least 1 dose of study medication.

Age, Customized
Age, Customized(Participants)Pregabalin (Single Blind Phase)
<18 years0
18 - 44 years178
45 - 64 years227
≥ 65 years36
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin (Single Blind Phase)
Female392
Male49
08

Study locations

52 sites
  • Andrew O. Schreiber, MD
    Orange, California 92868, United States
  • Apex Research Institute
    Santa Ana, California 92705, United States
  • Paddock Park Clinical Research
    Ocala, Florida 34474, United States
  • Broward Research Group
    Pembroke Pines, Florida 33026, United States
  • Meridien Research
    Tampa, Florida 33606, United States
  • Arthritis Care Center
    Moline, Illinois 61265, United States
  • Davis Clinic, Inc
    Indianapolis, Indiana 46250, United States
  • Central Kentucky Research Associates, Inc.
    Lexington, Kentucky 40509, United States
  • Commonwealth Biomedical Research, LLC
    Madisonville, Kentucky 42431, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Beacon Clinical Research, LLC
    Brockton, Massachusetts 02301, United States
  • The Center for Pharmaceutical Research, PC
    Kansas City, Missouri 64114, United States
  • Mercy Health Research
    Saint Louis, Missouri 63141, United States
  • Quality Clinical Research, Inc.
    Omaha, Nebraska 68114, United States
  • AB Clinical Trials
    Las Vegas, Nevada 89119, United States
  • Albuquerque Neuroscience, Incorporated
    Albuquerque, New Mexico 87109, United States
  • Social Psychiatry Research Institute
    Brooklyn, New York 11235, United States
  • Trinity Health Organization
    Minot, North Dakota 58701, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • Radiant Research,
    Columbus, Ohio 43212, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Sunstone Medical Research, LLC
    Medford, Oregon 97504, United States
  • Allegheny Pain Management
    Altoona, Pennsylvania 16602, United States
  • East Penn RheumatologyAssociates, P.C.
    Bethlehem, Pennsylvania 18015, United States
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • R/D Clinical Research, Inc.
    Lake Jackson, Texas 77566, United States
  • Fatigue Consultation Clinic
    Salt Lake City, Utah 84102, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22911, United States
  • Tacoma Center for Arthritis Research, PS
    Tacoma, Washington 98405-2308, United States
  • Dr. Alexander McIntyre Inc.
    Penticton, British Columbia V2A 4M4, Canada
  • Rivergrove Medical Clinic
    Winnipeg, Manitoba R2V 4W3, Canada
  • Maritime Research Center
    Bathurst, New Brunswick E2A 4X7, Canada
  • Clinique Medicale Nepisiguit
    Bathurst, New Brunswick E2A 4Z9, Canada
  • Tri-Hospital Sleep Laboratory West
    Mississauga, Ontario L5B 4M4, Canada
  • Canadian Phase Onward Inc.
    Toronto, Ontario M3H 5S4, Canada
  • Sleep & Alertness Research Inc.
    Toronto, Ontario M6J 3S3, Canada
  • West Island Rheumatology Research Associates
    Pointe Claire, Quebec H9R 3J1, Canada
  • Diex Research Sherbrooke Inc.
    Sherbrooke, Quebec J1H 1Z1, Canada
  • Groupe de Recherche en Rhumatologie et Maladie Osseuses (GRMO Inc.)
    Quebec, G1V 3M7, Canada
  • Mahavir Hospital & Research Centre
    Hyderabad, Andhra Pradesh 500 004, India
  • Chanre Rheumatology & Immunology Center & Research
    Bangalore, Karnataka 560 079, India
  • Deenanath Mangeshkar Hospital and Research Centre
    Pune, Maharashtra 411 004, India
  • Sahyadri Clinical Research & Development Center,
    Pune, Maharashtra 411 004, India
  • Sahyadri Speciality Hospital
    Pune, Maharashtra 411004, India
  • Punjab Rheumatology Centre
    Ludhiana, Punjab 141 001, India
  • Department of Rheumatology
    Lucknow, Uttar Pradesh 226 018, India
  • Indian Spinal Injuries Centre
    New Delhi, 110 070, India
  • Chang Gung Medical Foundation-Linkou Branch
    Kwei Shan Town, Taoyuan County 333, Taiwan
  • Chang-Hua Christian Hospital
    Changhua, 500, Taiwan
  • China Medical University Hospital
    Taichung, 404, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
09

References and documents

Publications

  • Arnold LM, Arsenault P, Huffman C, Patrick JL, Messig M, Chew ML, Sanin L, Scavone JM, Pauer L, Clair AG. Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. Curr Med Res Opin. 2014 Oct;30(10):2069-83. doi: 10.1185/03007995.2014.928275. Epub 2014 Jun 27. Erratum In: Curr Med Res Opin. 2017 Apr;33(4):795-796. doi: 10.1080/03007995.2017.1292446. PubMed 24867298 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Jul 2012, 16 months.

Results were first posted in Sep 2018, 6 years 2 months after primary completion. A results delay was requested in Aug 2013.

Of 17 phase 3 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2011
First posted
Jan 7, 2011
StartActual
Mar 2011
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results delay requested
Aug 30, 2013
Results first posted
Sep 14, 2018
Last update
Jan 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01271933
Responsible party
Sponsor
First posted
Jan 7, 2011
Start date
Mar 2011
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Sep 14, 2018
Last update
Jan 22, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion